Document is current
Any future updates will be listed below
-
Authors
Griffin, Gabriel K. https://orcid.org/0000-0002-4042-6757
Booth, Christopher A. G. https://orcid.org/0000-0003-3841-6637
Togami, Katsuhiro https://orcid.org/0000-0001-8422-0008
Chung, Sun Sook https://orcid.org/0000-0002-7340-3359
Ssozi, Daniel
Verga, Julia A.
Bouyssou, Juliette M. https://orcid.org/0000-0002-2301-0426
Lee, Yoke Seng
Shanmugam, Vignesh
Hornick, Jason L. https://orcid.org/0000-0001-6475-8345
LeBoeuf, Nicole R.
Morgan, Elizabeth A.
Bernstein, Bradley E.
Hovestadt, Volker https://orcid.org/0000-0002-3480-6649
van Galen, Peter https://orcid.org/0000-0002-0735-1570
Lane, Andrew A. https://orcid.org/0000-0001-7380-0226
- License Information
-
More Information
Article History
Received: 21 January 2021
Accepted: 2 May 2023
First Online: 7 June 2023
Competing interests
: B.E.B. discloses financial interests in Fulcrum Therapeutics, Chroma Medicine, HiFiBio, Arsenal Biosciences, Cell Signaling Technologies and Design Pharmaceuticals. A.A.L. received research funding from Abbvie and Stemline therapeutics, and consulting fees from Cimeio Therapeutics, IDRx, Jnana Therapeutics, N-of-One and Qiagen. P.v.G. received consulting fees from ManaT Bio and Immunitas.
